Home › Funds › Commodore Capital LP › SABS
Commodore Capital LP position in SABS
SAB BIOTHERAPEUTICS INC · Health Care
Commodore Capital LP reported holding 2,870,000 shares of SABS (SAB BIOTHERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$11.2M, representing 0.67% of its reported portfolio and ranking #26 among its reported holdings. Commodore Capital LP has disclosed SABS holdings in 6 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Commodore Capital LP's SABS position evolved
Commodore Capital LP first disclosed a stake in SABS in Q4 2023 at 1,831,746 shares (US$1.3M). The position peaked in Q1 2026 at 4,401,500 shares, worth US$16.9M. Across 6 filings, Commodore Capital LP increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 2,870,000 shares valued at US$11.2M — a reduction of -1,531,500 shares quarter over quarter.. Notable position changes include a 90% trim in Q1 2024 (shares fell 32% over the following quarter), a 35% trim in Q2 2026 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 1.83M | $1.26M | New |
| Q1 2024 | 183.17K | $831.61K | Reduce |
| Q3 2025 | 4.40M | $8.85M | New |
| Q4 2025 | 4.40M | $16.46M | Hold |
| Q1 2026 | 4.40M | $16.86M | Hold |
| Q2 2026 | 2.87M | $11.19M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SABS and 13F data
SABS (SAB BIOTHERAPEUTICS INC) is a Health Care company. 77 other funds we track also report a position in SABS — the largest reported positions include Caligan Partners LP (US$31.1M), Vivo Capital, LLC (US$28.5M), Spruce Street Capital LP (US$8.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SABS
- Caligan Partners LP 7.97M sh · $31.07M · Q2 2026
- Vivo Capital, LLC 7.30M sh · $28.47M · Q2 2026
- Spruce Street Capital LP 2.20M sh · $8.57M · Q2 2026
- Sessa Capital IM, L.P. 2.20M sh · $8.57M · Q2 2026
- Propel Bio Management, LLC 1.08M sh · $4.20M · Q2 2026
- Seven Fleet Capital Management LP 736.08K sh · $2.87M · Q2 2026
More on Commodore Capital LP
FAQ
How long has Commodore Capital LP held SABS?
Commodore Capital LP has disclosed SABS holdings in 6 of the last 11 reported quarters, going back to Q4 2023.
What is Commodore Capital LP's current position in SABS?
As of Q2 2026, Commodore Capital LP holds 2.87M shares of SABS (SAB BIOTHERAPEUTICS INC), valued at $11.19M, representing 0.67% of its reported portfolio and ranking #26.
Has Commodore Capital LP been buying or selling SABS?
In the latest 13F filing (Q2 2026), Commodore Capital LP reduced its position in SABS. The position peaked in Q1 2026 at 4.40M shares.
Which other funds hold SABS?
Other major institutional holders of SABS include Caligan Partners LP, Vivo Capital, LLC, Spruce Street Capital LP, among 77 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.